RPT1G in High Risk MDS
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemia Activity of RPT1G in Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 24 patients (estimated)
- Tags
- NAMPT Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2241
- NCT Identifier
- NCT07107126
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.